Skip to content

Released May 13, 2026, after the close

10-Q filed May 13, 2026, 43 days after period end · 0001193125-26-221591

Q1 2026 · 10-Q
Revenue$0.00−100.0% vs Q1 2025−100.0% vs Q4 2025
Net Income-$7.20MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.13N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$7,538,000N/M
Operating Cash Flow$15,864,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$0.00$12.00K$140.00K$223.00K
Net Income-$7.20M-$13.87M-$12.67M-$13.30M
EPS Diluted-$0.13-$0.25-$0.24-$0.25

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR